Abstract:With the increasing cost of drug development and clinical trials, it is of great value to make full use of all kinds of data to improve the efficiency of drug development and to provide valid information for medication guidelines. Model-based meta-analysis (MBMA) combines mathematical models with meta-analysis to integrate information from multiple sources (preclinical and clinical data, etc.) and multiple dimensions (targets/mechanisms, pharmacokinetics/pharmacodynamics, diseases/indications, populations, regimens, biomarkers/efficacy/safety, etc.), which not only provides decision-making for all key points of drug development, but also provides effective information for rational drug use and cost-effectiveness analysis. The classical meta-analysis requires high homogeneity of the data, while MBMA can combine and analyze the heterogeneous data of different doses, different time courses, and different populations through modeling, so as to quantify the dose-effect relationship, time-effect relationship, and the relevant impact factors, and thus the efficacy or safety features at the level of dose, time and covariable that have not been involved in previous studies. Although the modeling and simulation methods of MBMA are similar to population pharmacokinetics/pharmacodynamics (Pop PK/PD), compared with Pop PK/PD, the advantage of MBMA is that it can make full use of literature data, which not only improves the strength of evidence, but also can answer the questions that have not been proved or can not be answered by a single study. At present, MBMA has become one of the important methods in the strategy of model-informed drug development (MIDD). This paper will focus on the application value, data analysis plan, data acquisition and processing, data analysis and reporting of MBMA, in order to provide reference for the application of MBMA in drug development and clinical practice.

Mixture random effect model based meta-analysis for medical data mining

General Considerations of Model-Based Meta-Analysis

Simulation models for aggregated data meta-analysis: Evaluation of pooling effect sizes and publication biases

Sequential Estimation for Mixture of Regression Models for Heterogeneous Population

A latent topic model for mining heterogenous non-randomly missing electronic health records data

Adding Mendelian randomization to a meta-analysis-a burgeoning opportunity

Additive mixed models with approximate Dirichlet process mixtures: the EM approach

A Mixed Effect Similarity Matrix Regression Model (SMRmix) for Integrating Multiple Microbiome Datasets at Community Level and its Application in HIV

Semiparametric estimation of the nonmixture cure model with auxiliary survival information

Clustering and Meta-Analysis Using a Mixture of Dependent Linear Tail-Free Priors

Applications of Model-Based Meta-Analysis in Drug Development

Emulate randomized clinical trials using heterogeneous treatment effect estimation for personalized treatments: Methodology review and benchmark

Reciprocal causation mixture model for robust Mendelian randomization analysis using genome-scale summary data

Bayesian Model-Averaged Meta-Analysis in Medicine

Goodness-of-fit Test for Meta-Analysis

Exact inference for the random‐effect model for meta‐analyses with rare events

A demonstration and evaluation of the use of cross-classified random-effects models for meta-analysis

Comparing various Bayesian random‐effects models for pooling randomized controlled trials with rare events

Unsupervised Liu-type shrinkage estimators for mixture of regression models

Subgroup Analysis Using Bernoulli-gated Hierarchical Mixtures of Experts Models.

A Latent Mixture Model for Heterogeneous Causal Mechanisms in Mendelian Randomization